Europe Cell Counting Market

Europe Cell Counting Market Size (2023 to 2028)

The Europe cell counting market was valued at USD 0.31 billion in 2023. This value is further estimated to be growing at a CAGR of 6.8% between 2023 to 2028 and will be worth USD 0.43 billion by 2028.

Cell counters are becoming more widely used in various applications, including research, diagnostics, and industry. Cell counting instruments are increasingly being used in multiple fields of study, including cancer biology, immunology, and neuroscience, and the market is expected to grow exponentially. In addition, as the number of chronic diseases rise, the demand for tools increases.

The increased incidence of target diseases such as HIV, measles, and diphtheria and chronic diseases such as cancer and other blood disorders is primarily driving the European cell counting market expansion. According to the World Health Organization (WHO), almost 7.9 million people in Europe were infected with HIV in 2018. Most of this prevalence has been discovered in poor and middle-income nations. Furthermore, the government's increasing financing for cell counting research boosts industry growth. The market expansion is supplemented by inspiring attitudes toward stem cell research, increased funding, and widespread awareness of stem cells.

The rising frequency of AIDS and cancer is one of the primary factors driving the worldwide cell counting industry. Cell counting ensures intra-tumor heterogeneity, an essential step in tracking cancer growth in the patient's body. However, many people are hesitant to spend money on cell counting methods for medical or research purposes due to the high costs of the apparatus, equipment, and procedures. Furthermore, most countries have underdeveloped healthcare infrastructure and antiquated technology, severely hindering cell counting growth. Morseverely hindering cell counting growthcarcity of competent personnel.

The expansion of the market in Europe is being hampered by a scarcity of experienced professionals combined with insufficient research infrastructure, particularly in emerging markets.

This research report on the Europe cell counting market has been segmented and sub-segmented into the following categories.

By Product:

• Instruments
• Cell Counters
• Hematology Analysers
• Spectrophotometer
• Flow Cytometer
• Hemocytometer
• Others

Based on the product, the spectrophotometers segment is anticipated to play the leading role in the European cell counting market during the forecast period.

By Consumables:

• Microplates
• Reagent
• Assay Kits

By End User:

• Pharmaceutical & Biotechnology Industries
• Hospitals & Diagnostic Laboratories
• Research & Academic Institutes

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, Europe is expected to have the second-highest share of the global cell counting market during the forecast period owing to the growing patient population suffering from chronic diseases and the increasing aging population. Furthermore, the European cell counting market is expected to grow in the coming years due to the rising prevalence of chronic diseases and blood-related disorders, technological advancements in this segment, and the expanding biopharmaceutical and biotechnology industries.

The UK cell counting market held a promising share of the European market in 2022 and is expected to witness a notable CAGR during the forecast period owing to an increasing number of chronic diseases and a growing number of research and development programs. In addition, growing demand for high-tech instruments in research and diagnostic applications, high incidence of target conditions, increased focus on stem cell, biomedical, and cancer research, rising prevalence of chronic diseases, and growing demand for early diagnosis and effective treatment of diseases are all contributing to this segment's large share.

The German cell counting market is predicted to register a healthy CAGR in the coming years and hold a considerable share of the European market. The rising number of stem cell, genomics, and proteomic research activities, the vast genome pool, the growing trend for research infrastructure modernization, low development costs, less complicated regulations, and increasing investments by pharmaceutical and biotechnology companies contribute to this growth.

Other countries such as Spain, Italy, and France are anticipated to witness a steady growth rate during the forecast period.

KEY MARKET PLAYERS

Thermo Fisher Scientific, Inc., Danaher Corporation, Agilent Technologies, Bio-Rad Laboratories, Merck Millipore, Inc., GE Healthcare, Becton, Dickinson and Company, and PerkinElmer, Inc. are some of the noteworthy companies in the European cell counting market.